DiscoverAbout XenTech
XenTech is dedicated to accelerating the development of new anti-cancer therapies by providing with the most relevant science-driven preclinical services to our clients and partners.
XenTech pioneered the Patient-Derived primary tumor Xenograft models (PDX) approach and was one of the first CRO proposing this technology to the indsutry and oncology research community.
Our expertise and technology were forged on one of the world’s reference and most published PDX collection.
Our ambition is to foster therapeutic development in Oncology by offering an innovative translational platform, developing clinically relevant tumor models and addressing tomorrow’s needs in preclinical oncology research.
01Our company
XenTech is a spin-off of Institut Curie, France’s largest cancer research institute, where our scientists have published reference articles since 1989, providing the world’s first proof of concept for the development and use of PDXs.
With over 2500 studies carried out with industrial and academic partners, XenTech’s staff has a comprehensive knowledge of PDX based experimental pharmacology.
Our team ensures high quality research and ethical standards and is continuously working to keep up-to-date with new technologies.
02Our team
XenTech’s staff is composed of highly trained and dynamic researchers, engineers and technicians with a solid experience in experimental pharmacology, tumor xenograft models, as well as molecular and cell biology. The whole team works together to keep up with scientific and technical excellence and new technologies.
XenTech aim to comply with the highest quality standards. Our efforts translate into trust relationship and delivery of reliable data that meet the highest industrial standards.
03Our team
Thomas Janvier
CEOCEO XenTech
CEO Janvier Group Biosciences
Vincent Verbiest
PhD, Business DeveloperVincent earned his PhD from the anti-cancer institute of Bordeaux and worked on the identification and characterization of genes modulating the sensitivity to anti-cancer agents targeting the DNA integrity.
Following a post-doc at the Erasmus Medical Center of Rotterdam where he worked on the deciphering of the Nucleotide Excision Repair machinery, Vincent developed and managed studies for more than 10 years in different preclinical CROs, mainly in the field of oncology and immune-oncology.
As Business Developer, Vincent explores and assists, alongside the whole team, every opportunity allowing to support preclinical programs in oncology with the PDX/PDX DC models and related services of Xentech.
Marie CAUSSOU
Chief Financial Officer & HR ManagerExperimented CFO, with wide experience in several SME companies, both in B2C and B2B activities. Marie is in charge of financial well-being of the organization, financial projections, accounting services as well as Human Resources management. She masters financial strategies by forecasting capital, facilities, and staff requirements; identifies monetary resources and develops action plans.
Marie TAVERNIER
MSc. (Study Director Team Lead, Contract Research Dept)Marie was promoted to Study Director in April 2012. Prior to that she worked for 4 years in the field of preclinical oncology including 3 years at XenTech where she acquired an extensive knowledge of in vivo PDX studies and project management. Marie received a Master degree in bio-industrial technologies from Orléans University (France) in 2007.
She leads the Study Director team since 2022.
Olivier DEAS
CSOOlivier has over 20 years of research experience in the field of immunology and oncology. He received his Ph.D in 1999 from University Paris Sud XI. Before he joined XenTech, he developed an original system of gene therapy targeted by antibody at Bioprotein Technologies and at Targatherapies, where he was in charge of the R&D. Then, Olivier was Head of the Oncology department (vitro and vivo) at Theraptosis (Pasteur Institute, Paris) and Manager of XenTech’s cell biology department.
Laurent de SAINT RAPT
Quality ManagerLaurent is an experienced Laboratory Animal Technician. Before working at XenTech, he worked at the CERB and Pierre Fabre Laboratories. He has over 20 years of experience in the field of toxicology and pharmacology studies in a GLP environment. At XenTech, Laurent is in charge of the implementation of the quality management system. He coordinates the improvement actions and manages the documentary system.
Emilie INDERSIE
Ph.D. (Study Director, R&D and Contract Research Dept)Emilie received her Ph.D. degree in Cellular Biology and Physiopathology in 2016 from Bordeaux University (INSERM U1035, Bordeaux). She has a 7 years’ academic experience in the field of pediatric cancer.
During her Ph.D., she conducted in vitro and ex vivo studies on hepatoblastoma cell lines and PDX models for which she established molecular characterizations. She then moved to Curie Institute (UMR 3347/U1021, Curie Institute, Orsay) where she worked on medulloblastoma PDX models and participated to the establishment and the multi-omics characterization of a large cohort of medulloblastoma patient tumors.
Since she joined Xentech in 2021, she is in charge of the project management of in vitro and in vivo studies for R&D projects as well as Contract Research Services. She also is responsible for managing molecular data and for the PDX models molecular characterization.
Delphine NICOLLE
Ph.D. (Study Director, Contract Research Dept)Delphine received her Ph.D. degree in Biological Sciences from Orléans University (France) in 2004. She has an academic experience in molecular immunology and embryology, and she worked as study manager at the CNRS UMR6218 lab in Orléans. Delphine joined XenTech in 2008. . Delphine is responsible for managing in vivo efficacy studies in our preclinical research services department.
Marie TAVERNIER
MSc. (Study Director Team Lead, Contract Research Dept)Marie was promoted to Study Director in April 2012. Prior to that she worked for 4 years in the field of preclinical oncology including 3 years at XenTech where she acquired an extensive knowledge of in vivo PDX studies and project management. Marie received a Master degree in bio-industrial technologies from Orléans University (France) in 2007.
She leads the Study Director team since 2022.
Thomas Janvier
CEOCEO XenTech
CEO Janvier Group Biosciences
Vincent Verbiest
PhD, Business DeveloperVincent earned his PhD from the anti-cancer institute of Bordeaux and worked on the identification and characterization of genes modulating the sensitivity to anti-cancer agents targeting the DNA integrity.
Following a post-doc at the Erasmus Medical Center of Rotterdam where he worked on the deciphering of the Nucleotide Excision Repair machinery, Vincent developed and managed studies for more than 10 years in different preclinical CROs, mainly in the field of oncology and immune-oncology.
As Business Developer, Vincent explores and assists, alongside the whole team, every opportunity allowing to support preclinical programs in oncology with the PDX/PDX DC models and related services of Xentech.
Emilie INDERSIE
Ph.D. (Study Director, R&D and Contract Research Dept)Emilie received her Ph.D. degree in Cellular Biology and Physiopathology in 2016 from Bordeaux University (INSERM U1035, Bordeaux). She has a 7 years’ academic experience in the field of pediatric cancer.
During her Ph.D., she conducted in vitro and ex vivo studies on hepatoblastoma cell lines and PDX models for which she established molecular characterizations. She then moved to Curie Institute (UMR 3347/U1021, Curie Institute, Orsay) where she worked on medulloblastoma PDX models and participated to the establishment and the multi-omics characterization of a large cohort of medulloblastoma patient tumors.
Since she joined Xentech in 2021, she is in charge of the project management of in vitro and in vivo studies for R&D projects as well as Contract Research Services. She also is responsible for managing molecular data and for the PDX models molecular characterization.
Marie CAUSSOU
Chief Financial Officer & HR ManagerExperimented CFO, with wide experience in several SME companies, both in B2C and B2B activities. Marie is in charge of financial well-being of the organization, financial projections, accounting services as well as Human Resources management. She masters financial strategies by forecasting capital, facilities, and staff requirements; identifies monetary resources and develops action plans.
Delphine NICOLLE
Ph.D. (Study Director, Contract Research Dept)Delphine received her Ph.D. degree in Biological Sciences from Orléans University (France) in 2004. She has an academic experience in molecular immunology and embryology, and she worked as study manager at the CNRS UMR6218 lab in Orléans. Delphine joined XenTech in 2008. . Delphine is responsible for managing in vivo efficacy studies in our preclinical research services department.
Marie TAVERNIER
MSc. (Study Director Team Lead, Contract Research Dept)Marie was promoted to Study Director in April 2012. Prior to that she worked for 4 years in the field of preclinical oncology including 3 years at XenTech where she acquired an extensive knowledge of in vivo PDX studies and project management. Marie received a Master degree in bio-industrial technologies from Orléans University (France) in 2007.
She leads the Study Director team since 2022.
Olivier DEAS
CSOOlivier has over 20 years of research experience in the field of immunology and oncology. He received his Ph.D in 1999 from University Paris Sud XI. Before he joined XenTech, he developed an original system of gene therapy targeted by antibody at Bioprotein Technologies and at Targatherapies, where he was in charge of the R&D. Then, Olivier was Head of the Oncology department (vitro and vivo) at Theraptosis (Pasteur Institute, Paris) and Manager of XenTech’s cell biology department.
Laurent de SAINT RAPT
Quality ManagerLaurent is an experienced Laboratory Animal Technician. Before working at XenTech, he worked at the CERB and Pierre Fabre Laboratories. He has over 20 years of experience in the field of toxicology and pharmacology studies in a GLP environment. At XenTech, Laurent is in charge of the implementation of the quality management system. He coordinates the improvement actions and manages the documentary system.
04Our values
XenTech aims to comply with the highest quality standards. Our efforts translate into trusted relationship and delivery of reliable data that meet the highest industrial standards.
PDX are not only models to study tumor progression, resistance and treatment. The use of PDX is tightly associated with a solid know-how, high ethical standards, and strong dedication. Thanks to its quality system and the dedication of its employees, XenTech provides the highest quality data for your experiments.
All studies are carried out within a modern state-of-the-art vivarium by our committed specialists with exceptionally strong scientific and technical expertise.
Our carefully selected and validated models are of high clinical predictivity. Thanks to the experience of our scientific team we are able to select the right model for you and offer high quality customized solutions specifically to your needs.
During the past 15 years, we have worked with worldwide clients of all size and delivered high-quality data for over 2500 in vivo studies.
05Our vision
- values
Faithfully
reproducing the biological features of human cancers in term of histology, genomics and proteomics
Providing
established concordance between patient and xenograft drug responses
Covering
molecular diversity of clinical disease
Allowing
identification of responsive cancer types
Allowing
biomarker exploratory studies for subsequent patient stratification
